Spots Global Cancer Trial Database for Amivantamab in Adenoid Cystic Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Amivantamab in Adenoid Cystic Carcinoma
Official Title: Phase II Study to Evaluate Amivantamab in Recurrent and Metastatic Adenoid Cystic Carcinoma
Study ID: NCT05074940
Conditions
Interventions
Study Description
Brief Summary: The purpose of the study is to determine if treatment with amivantamab will be efficacious in patients with recurrent and metastatic adenoid cystic carcinoma.
Detailed Description: ACC is a rare cancer of salivary glands and other glandular tissue. It is slow growing and is usually treated with surgery and radiation. However, this type of cancer tends to have a high rate of recurrence and metastatic spread, which develops over several years. We hypothesize that amivantamab, a bispecific EGFR and MET inhibitor will be efficacious in ACC. Patients will receive amivantamab at 1050mg weekly for the first cycle and biweekly thereafter (1400mg for patients ≥80kg).
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UC San Diego Moores Cancer Center, La Jolla, California, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Rogel Cancer Center - University of Michigan Health, Ann Arbor, Michigan, United States
Washington University - School of Medicine in St. Louis, Saint Louis, Missouri, United States
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
Contact Details
Name: Trisha Wise-Draper, MD, PhD
Affiliation: University of Cincinnati
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
